Hostname: page-component-cb9f654ff-c75p9 Total loading time: 0 Render date: 2025-08-12T12:10:21.119Z Has data issue: false hasContentIssue false
  • English
  • Français

Comparison of the efficacy of patient self-application versus physician application of triamcinolone acetonide econazole cream in the treatment of otomycosis: a randomized open-label controlled trial

Published online by Cambridge University Press:  31 March 2025

Chunsheng Ye Open the ORCID record for Chunsheng Ye [Opens in a new window] ,
Yongjun Hong Open the ORCID record for Yongjun Hong [Opens in a new window]  and
Yahong Cai
Chunsheng Ye
Affiliation:
Department of Otolaryngology-Head and Neck Surgery, Zhongshan Hospital of Xiamen University, Xiamen, China
Yongjun Hong*
Affiliation:
Department of Otolaryngology-Head and Neck Surgery, Zhongshan Hospital of Xiamen University, Xiamen, China
Yahong Cai
Affiliation:
Department of Science Education and Research, Jinjiang Municipal Hospital Jinnan Branch, Quanzhou, China
*
Corresponding author: Yongjun Hong; Email: 13400661815@163.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives

To explore methods for accurate diagnosis and effective treatment of otomycosis.

Methods

Using randomised stratification, eligible patients were split into a patient-applied medication group and a physician-applied medication group in order to compare the efficacy and recurrence rates of two treatment approaches.

Results

The primary symptom of otomycosis was ear blockage (35.2 per cent), followed by pruritis (26.7 per cent) and otorrhea (13.6 per cent). Predominant fungi were Aspergillus terreus (50.5 per cent), Candida parapsilosis (15.5 per cent) and Aspergillus niger (12.5 per cent). The treatment efficacy was 44.7 per cent (34/76) for the patient-applied medication group and 98.6 per cent (71/72) for the physician-applied medication group, with the difference being statistically significant (χ2 = 52.061, p <0.01). The recurrence rate was 35.3 per cent (12/34) for the patient-applied group and 2.8 per cent (2/71) for the physician-applied medication group, also showing a statistically significant difference (p <0.01).

Conclusion

Triamcinolone acetonide econazole cream application by a physician every 2–3 days, three times, effectively cures otomycosis and lowers recurrence.

Keywords

otomycosistriamcinolone acetonideeconazoletreatment efficacy

Information

Type
Main Article
Information
The Journal of Laryngology & Otology , First View , pp. 1 - 6
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of J.L.O. (1984) LIMITED.

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

Footnotes

Yongjun Hong takes responsibility for the integrity of the content of the paper

References

Ho, T, Vrabec, JT, Yoo, D, Coker, NJ. Otomycosis: clinical features and treatment implications. Otolaryngol Head Neck Surg 2006;135:787–91Google Scholar
Anwar, K, Gohar, MS. Otomycosis; clinical features, predisposing factors and treatment implications. Pak J Med Sci 2014;30:564–7Google Scholar
Prasad, SC, Kotigadde, S, Shekhar, M, Thada, ND, Prabhu, P, D’Souza, T, et al. Primary otomycosis in the Indian subcontinent: predisposing factors, microbiology, and classification. Int J Microbiol 2014;2014:636493Google Scholar
Mugliston, T, O’Donoghue, G. Otomycosis—a continuing problem. J Laryngol Otol 1985;99:327–33Google Scholar
Kaur, R, Mittal, N, Kakkar, M, Aggarwal, AK, Mathur, MD. Otomycosis: a clinicomycologic study. Ear Nose Throat J 2000;79:606–9Google Scholar
Garcia-Agudo, L, Aznar-Marin, P, Galán-Sánchez, F, García-Martos, P, P, Marin-Casanova, Rodríguez-Iglesias, M. Otomycosis due to filamentous fungi. Mycopathologia 2011;172:307–10Google Scholar
Ali, K, Hamed, MA, Hassan, H, Esmail, A, Sheneef, A. Identification of fungal pathogens in otomycosis and their drug sensitivity: our experience. Int Arch Otorhinolaryngol 2018;22:400–3Google Scholar
Nemati, S, Hassanzadeh, R, Khajeh Jahromi, S, Delkhosh Nasrollah Abadi, A. Otomycosis in the north of Iran: common pathogens and resistance to antifungal agents. Eur Arch Otorhinolaryngol 2014;271:953–7Google Scholar
Jia, X, Liang, Q, Chi, F, Cao, W. Otomycosis in Shanghai: aetiology, clinical features and therapy. Mycoses 2012;55:404–9Google Scholar
Kurnatowski, P, Filipiak, A. Otomycosis: prevalence, clinical symptoms, therapeutic procedure. Mycoses 2001;44:472–9Google Scholar
Enoz, M, Sevinc, I, Lapeña, JF. Bacterial and fungal organisms in otitis externa patients without fungal infection risk factors in Erzurum, Turkey. Braz J Otorhinolaryngol 2009;75:721–5Google Scholar
Dundar, R, Iynen, I. Single dose topical application of clotrimazole for the treatment of otomycosis: is this enough? J Audiol Otol 2018;23:15–19Google Scholar
del Palacio, A, Cuétara, MS, López-Suso, MJ, Amor, E, Garau, M. Randomized prospective comparative study: short-term treatment with ciclopiroxolamine (cream and solution) versus boric acid in the treatment of otomycosis. Mycoses 2002;45:317–28Google Scholar
Xu, S, Li, J, Ding, L, Gao, K, Xie, F, Han, J, et al. Efficacy and safety of terbinafine hydrochloride spray and 3% boric acid alcohol ear drops in otomycosis. Acta Otolaryngol 2020;140:302–6Google Scholar
Romsaithong, S, Tomanakan, K, Tangsawad, W, Thanaviratananich, S. Effectiveness of 3 per cent boric acid in 70 per cent alcohol versus 1 per cent clotrimazole solution in otomycosis patients: a randomised, controlled trial. J Laryngol Otol 2016;130:811–15Google Scholar
Chen, Q, Chu, H, Tao, Y, Peng, L, Zhou, L, Liu, L, et al. A comparison of triamcinolone acetonide econazole cream and nystatin suspension in treatment of otomycosis. Laryngoscope 2021;131:E1640–6Google Scholar
Munguia, R, Daniel, SJ. Ototopical antifungals and otomycosis: a review. Int J Pediatr Otorhinolaryngol 2008;72:453–9Google Scholar